Headquarters
France
Every company in the roster headquartered in France.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
11 of 11 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 SanofiSNY · Nasdaq | 37 assets: 14 approved, 7 Ph 3, 10 Ph 2, 6 Ph 1 | Ciclesonide (XRP1526)Phase 3 · AsthmaReliable signal | 7 Oct 2026dupilumab · Phase 3 |
 Pierre Fabre MedicamentPrivate | 4 assets: 3 Ph 2, 1 Ph 1 | STX-241Phase 1/2 · Non-Small Cell Lung Cancer | 20 Nov 2027STX-241 · Phase 1/2 |
 ServierPrivate | 4 assets: 1 Ph 3, 3 Ph 2 | IvosidenibPhase 3 · Acute Myeloid Leukemia | 31 Dec 2026Ivosidenib · Phase 1 |
 AB ScienceAB · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | MasitinibPhase 3 · Alzheimer's DiseaseReliable signal | Dec 2027Masitinib · Phase 3 |
 AbivaxABVX · Nasdaq | 1 asset: 1 Ph 3 | obefazimodPhase 3 · Ulcerative ColitisReliable signal | Dec 2026obefazimod · Phase 2 |
 Advanced BioDesignPrivate | 1 asset: 1 Ph 2 | ABD-3001Phase 1/2 · Acute Myeloid Leukemia | None on record |
 InventivaIVA · Nasdaq | 1 asset: 1 Ph 3 | LanifibranorPhase 3 · Type 2 DiabetesPartial signal | 30 Sep 2027Lanifibranor · Phase 3 |
| 1 asset: 1 Ph 2 | NanoLithium NP03Phase 2 · Alzheimer's DiseasePartial signal | None on record | |
 Orano Med Theranostics, SASPrivate | 1 asset: 1 Ph 1 | Pb-DOTAM-GRPR1Phase 1 · Non-Small Cell Lung Cancer | Jan 2027Pb-DOTAM-GRPR1 · Phase 1 |
| 1 asset: 1 Ph 1 | Leucettinib-21Phase 1 · Alzheimer's DiseasePartial signal | None on record | |
 TherAguixPrivate | 1 asset: 1 Ph 2 | AGuIXPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).